1. Ahmann DL, O'Connell MI, Bisel HF, Edmondson JH, Hahn RG, Frytak S (1977) Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer Treat Rep 61: 81?82
2. Bence J, Somfai-Relle S, Gáti É (1986) Development and some characteristics of a P388 leukemia strain resistant to 1,2:5,6-dianhydrogalactitol. Eur J Cancer Clin Oncol 22: 773?780
3. Csányi E, Halász M (1967) Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol (DBM)-resistant Yoshida s. c. sarcoma. Br J Cancer 21: 353?357
4. Eagan RT, Ames MM, Powis G, Kovach JS (1982) Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol. Cancer Treat Rep 66: 283?287
5. Eagan RT, Dinapoli RP, Hermann RC, Groover RV, Layton DD, Scott M (1982) Combination of carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. Cancer Treat Rep 66: 1647?1649